

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
18 January 2024 (18.01.2024)



(10) International Publication Number  
**WO 2024/015566 A1**

(51) International Patent Classification:  
*A61K 31/443* (2006.01) *A61P 35/00* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/US2023/027761

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:  
14 July 2023 (14.07.2023)

(25) Filing Language: English

(26) Publication Language: English

**Published:**

- with international search report (Art. 21(3))

(30) Priority Data:  
63/389,436 15 July 2022 (15.07.2022) US  
63/413,323 05 October 2022 (05.10.2022) US  
63/455,024 28 March 2023 (28.03.2023) US

(71) Applicant: **CONSTELLATION PHARMACEUTICALS, INC.** [US/US]; 470 Atlantic Avenue, Suite 1401, Boston, MA 02210 (US).

(72) Inventors: **WHICHER, Elizabeth, Adams**; 470 Atlantic Avenue, Suite 1401, Boston, MA 02210 (US). **YU, Ziyang**; 470 Atlantic Avenue, Suite 1401, Boston, MA 02210 (US). **SUN, Kaiming**; 24 Charles St., Belmont, MA 02478 (US). **KELLER, Patricia, Joyce**; 470 Atlantic Avenue, Suite 1401, Boston, MA 02210 (US). **TROJER, Patrick**; 57 Longwood Rd, Reading, 01867 (US).

(74) Agent: **DEGRAZIA, Michael, J.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF AT-RICH INTERACTIVE DOMAIN-CONTAINING PROTEIN 1A (ARID1A) MUTATED CANCERS

(57) Abstract: Provided herein are methods of treating cancers having at least one ARID 1 A mutation with (R)-7-chloro-2-((1R,4R)-4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydro-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharmaceutically acceptable salt thereof.

WO 2024/015566 A1